Change history 23 June 2026 Editors Note: The Editorial team is currently investigating questions raised about the data presented in the article
Ipamorelin At-Home Blood Test Research Supplies Disclosure: supply links may earn PDP a commission at no cost to you
SURMOUNT-5 trial
Similarly, tirzepatide, a dual GLP-1/GIP receptor agonist, achieved an average weight loss of 15% at 72 weeks in non-diabetic obese patients, with greater reductions observed at the higher 15 mg dose.77 The most frequently reported adverse effects of GLP-1RAs include nausea, vomiting, and diarrhea, which are dose-dependent and more prevalent with short-acting formulations than with long-acting agents
[2] Research suggests GHK-Cu may stimulate fibroblasts, the cells responsible for producing collagen and other connective tissue components
A consultation with our medical team and comprehensive sleep assessment are required to determine if this therapy is appropriate for you.